Candel Therapeutics, Inc. (CADL)

$1.9

+0.10 (+5.56%)
Rating:
Recommendation:
-
Symbol CADL
Price $1.9
Beta 0.000
Volume Avg. 0.04M
Market Cap 54.899M
Shares () -
52 Week Range 1.47-10.025
1y Target Est -
DCF Unlevered CADL DCF ->
DCF Levered CADL LDCF ->
ROE -20.18% Sell
ROA -14.25% Sell
Operating Margin -
Debt / Equity 63.08% Buy
P/E -1.35 Sell
P/B 1.05 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CADL news


Healthcare
Biotechnology
NASDAQ Global Market

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.